产品中心Cell Resources
联系我们CONTACT US
- 400-999-210024小时服务热线
产品概述
名称 | K7M2 wt [K7M2-WT] (小鼠骨肉瘤成骨细胞) (STR鉴定正确) |
别称 | K7M2 wt; K7M2 |
种属 | 小鼠 |
生长特性 | 贴壁细胞 |
细胞形态 | 成骨细胞样 |
冻存条件 | 冻存液:55% 基础培养基+40%FBS+5%DMSO 温度:液氮 |
培养方案A(默认) |
培养条件:
气相:空气,95%;CO2,5%, 温度:37℃
|
推荐传代比例 | 1:3-1:4 |
推荐换液频率 | 2-3次/周 |
背景描述 | K7M2 wt [K7M2-WT]细胞抗原表达:Ⅷ因子、整合唾液酸蛋白(BSP)、二聚糖、饰胶蛋白聚糖、绒毛蛋白。此外,骨唾液酸蛋白、二聚糖、饰胶蛋白聚糖和骨调素的表达显示K7M2 wt [K7M2-WT]细胞骨家族细胞特性。 |
年龄(性别) | 雌性;成年 |
组织来源 | 品系:BALB/c;器官:骨;疾病:骨肉瘤;来源转移灶:肺;细胞类型:成骨细胞 |
细胞类型 | 肿瘤细胞 |
肿瘤类型 | 肉瘤细胞 |
生物安全等级 | BSL-1 |
倍增时间 | ~31 hours |
致瘤性 | Yes, forms tumors in BALB/c mice with spontaneous metastasis to the lungs in over 90% of mice inoculated. |
抗原表达情况 | CD31+ |
基因表达情况 | secreted phosphoprotein 1 (osteopontin); factor VIII |
保藏机构 | ATCC; CRL-2836 |
STR鉴定
-
STR位点信息
18-3 18 6-7 12 5-5 14 X-1 25 1-2 17 7-1 29 8-1 13,14 1-1 16 19-2 13 15-3 22.3 12-1 17 6-4 18 4-2 21.3 3-2 12,13 2-1 16 13-1 16.2
11-2 18 17-2 16,17 -
STR鉴定图
参考文献
-
A bone-targeting permeable nanomicelle acting as an icebreaker for enhancing chemotherapy of osteosarcoma(2024/03/29)
作者:Bowen Duan, Hongting Liu, Xiaoxuan Ji
期刊:CHEMICAL ENGINEERING JOURNAL
影响因子 :15.100
引用产品:CL-0371
-
Nanoengineering a metal–organic framework for osteosarcoma chemo-immunotherapy by modulating indoleamine-2,3-dioxygenase and myeloid-derived suppressor cells(2022/05/03)
作者:Qingxin Fan, Jing Zuo, Hailong Tian
期刊:JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
DOI:10.1186/s13046-022-02372-8
影响因子 :11.300
引用产品:CL-0371
-
Tumor-oriented and chemo-photothermal nanoplatform capable of sensitizing chemotherapy and ferroptosis against osteosarcoma metastasis(2024/05/08)
作者:Hongzi Wu, Bowen Li, Jichun Shao
期刊:INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
DOI:10.1016/j.ijbiomac.2024.132019
影响因子 :8.200
引用产品:CL-0371
-
Injectable thermosensitive black phosphorus nanosheet- and doxorubicin-loaded hydrogel for synergistic bone tumor photothermal-chemotherapy and osteogenesis enhancement(2023/03/25)
作者:Shihuai Li, Yunan Qing, Yan Lou
期刊:INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
DOI:10.1016/j.ijbiomac.2023.124209
影响因子 :8.200
-
Investigating the synergy of Shikonin and Valproic acid in inducing apoptosis of osteosarcoma cells via ROS-mediated EGR1 expression(2024/02/15)
作者:Zhuo Chen, Fengfeng Wu, Jing Li
期刊:PHYTOMEDICINE
DOI:10.1016/j.phymed.2024.155459
影响因子 :7.900
引用产品:CL-0371
-
MerTK-mediated efferocytosis promotes immune tolerance and tumor progression in osteosarcoma through enhancing M2 polarization and PD-L1 expression(2022/01/12)
作者:Jinti Lin, Ankai Xu, Jiakang Jin
期刊:OncoImmunology
DOI:10.1080/2162402X.2021.2024941
影响因子 :7.200
-
Pharmacodynamics and pharmacokinetics of PLGA-based doxorubicin-loaded implants for tumor therapy(2022/02/29)
作者:Peng He, Shenglin Xu, Zehao Guo
期刊:Drug Delivery
DOI:10.1080/10717544.2022.2032878
影响因子 :6.000
引用产品:CL-0371
-
Sulfatinib, a novel multi-targeted tyrosine kinase inhibitor of FGFR1, CSF1R, and VEGFR1–3, suppresses osteosarcoma proliferation and invasion via dual role in tumor cells and tumor microenvironment(2023/06/08)
作者:Song Liao, Jianxiong Li, Song Gao
期刊:Frontiers in Oncology
影响因子 :4.700
-
LPS combined with CD47mAb enhances the anti‑osteosarcoma ability of macrophages(2023/03/28)
作者:Peng Yuan, Yukang Que, Yulei Liu
期刊:Oncology Letters
影响因子 :2.900
FAQs
Q:{{item.question}}
A:
产品资料
识别码示意图